| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Third Harmonic Bio, Inc.$5.38
-0.03 (-0.55%)
F 16Pipeline Score Richly Valued Pharma · Clinical
Market Cap
242.79 M
EPS
-1.24
P/E Ratio
-
Value Trade
7.61 M
-1.28 %
Week
-0.92 %
1 Month
4.06 %
3 Month
0 %
6 Month
-73.76 %
5 Year
-73.76 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.42 M
52 Week Range
3.18 - 16.02
% held by Insiders
50.6 %
% held by Institutions
39.45 %
Enterprise Value
-25.82 M
Total Shares
45.13 M
Short %
6.4 %
Float Shares
22.29 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-03-02 | THB335 (oral small molecule inhibitor of KIT) | Phase 1 data readout | Phase 1 | — | – | – | – |
2025-03-02 | THB335 (oral small molecule inhibitor of KIT) | Phase 1 data readout | Phase 1 | — | – | – | – |
2025-03-02 | THB335 (oral small molecule inhibitor of KIT) | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
F16
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 12%
Micro Cap (rank 813 of 923)
Percentile RankThird Harmonic Bio, Inc. has significant pipeline risk (16/100), with $106M risk-adjusted pipeline value, led by THB335 single dose in Healthy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THB335 single dose Small molecule | Healthy | Phase 1 | NCT06425861 | 7% | $106M | COMPLETED | 60 | - | - | Dec 18, 2024 | - | Dec 19, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
THB335 | chronic spontaneous urticaria | Phase 1 | 2025-02-11 | SAD: n 48, dose levels 21, 41, 82, 164, 205, half life approximately 40 hours, exposure trough plasma exposures exceeding the KIT IC90 at MAD dose levels of 41 mg QD and greater; MAD: n 32, dose levels 21, 41, 82, 205, mean reductions from baseline min 13, max 84 Read More | Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update Read More | |
THB335 | chronic spontaneous urticaria | Phase 1 | 2025-02-11 | SAD: n 48, dose levels 21, 41, 82, 164, 205, half life approximately 40 hours, exposure trough plasma exposures exceeding the KIT IC90 at MAD dose levels of 41 mg QD and greater; MAD: n 32, dose levels 21, 41, 82, 205, mean reductions from baseline min 13, max 84 Read More | Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update Read More | |
THB335 | chronic spontaneous urticaria | Phase 1 | 2025-02-11 | SAD: n 48, dose levels 21, 41, 82, 164, 205, half life approximately 40 hours, exposure trough plasma exposures exceeding the KIT IC90 at MAD dose levels of 41 mg QD and greater; MAD: n 32, dose levels 21, 41, 82, 205, mean reductions from baseline min 13, max 84 Read More | Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in THRD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
THRD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How THRD ranks across every disease it competes inCompetitive Position is a premium feature
See how THRD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial